About Naari
Naari is a Healthcare company based in Noida (India) founded in 2007 by Prithi S Kochhar, and was acquired by Tenshi Life Sciences in May 2017. It operates as a women care medicines are manufactured by Naari in India. Naari has raised $18.98 million across 3 funding rounds from investors including Jagsonpal, Ascent Capital and Tenshi Life Sciences. The company has 186 employees. Naari was last valued at $86.27 million in December 2019. Its chief executive is Prithi S Kochhar. Its Indian entity Naari Pharma Private Limited reported revenue of ₹136 Cr. Its focus areas include Life Sciences, Women Health, Drugs and Reproductive Diseases. Its competitors include Sprout Pharmaceuticals, ObsEva, Hope Medicine, Rejoni and Gameto and 3 more; 8 of its 8 listed competitors have raised funding.
Company details
Naari manufacturer of women care medicines, focusing on life sciences, women health, drugs, and reproductive diseases. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Noida, India
- Employees 186
- Founders Prithi S Kochhar
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website naari.co
- Social LinkedIn
- Acquired by Tenshi Life Sciences (May 2017)
- Legal Name Naari Pharma Private Limited
- Date of Incorporation 23 Feb, 1978
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹136 Cr
FY 2025 · +14% YoY
- Net Profit₹33.69 Cr
FY 2025 · 25% margin
- EBITDA₹40.19 Cr
FY 2025 · 29% margin
- Total Equity Funding$18.98M (USD)
in 3 rounds
- Latest Funding Round$17.53M (USD), Private Equity Round
Dec 2019
- InvestorsJagsonpal
& 3 more
- Employee Count186
- Acquired byTenshi Life Sciences
(May 2017)
Associated legal entities of Naari
Naari operates through Naari Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Naari Pharma Private Limited CIN U74899KA1978PTC142872 | Active | 23 Feb 1978 | Bangalore, Karnataka | ₹136 Cr | 186 | 5 | View details |
Funding Insights of Naari
Naari has successfully raised a total of $18.98M across 3 strategic funding rounds. The most recent funding activity was a Private Equity Round of $17.53 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.98M
- Total Rounds 3
- Last Round Private Equity Round — $17.53M
- First Round $53,694
(Dec 2008)
- Investors Count 3
All 3 funding rounds of Naari with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2019 | $17.53M | Private Equity Round | $86.27M | Ascent Capital | – |
| Oct 2019 | $1.45M | Series A | $48.08M | Jagsonpal | – |
| Dec 2008 | $53,694 | Grant | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Dec 2019 | $86.27M | •••••••• |
| Oct 2019 | $48.08M | •••••••• |
Last known valuation $86.27M (Dec 2019). 4 investors in total: 4 institutional.
Investors in Naari
Naari has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Jagsonpal, Ascent Capital and Tenshi Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
AscentCapital is engaged in potato farming, grain marketing, and equipment services in Maine. | 2000 | ascentcapital.in | Bengaluru, India | |
Traditional company manufacturing bulk drugs and finished formulations | 1964 | jagsonpal.com | Delhi, India | |
Resources and assistance are provided to HUD's community partners. | – | hudexchange.info | United States | |
Delivers advanced finished dosage pharmaceuticals using global infrastructure and quality systems. | 2007 | tenshi.co.in | Bengaluru, India |
Investor details for Naari
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Naari Pharma Private Limited (Naari)
Naari Pharma Private Limited is the primary company behind Naari. The board of Naari Pharma Private Limited currently have 4 directors; the longest-serving is Prithipal Singh Kochhar, appointed in 2015. 12 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Prithipal Singh Kochhar DIN 01052194 | Whole-time director | 15 Apr 2015 | 11 yrs 6 mo | Naari Pharma Private Limited |
| Deepak Komaregowda DIN 03298261 | Nominee Director | 06 Dec 2019 | 6 yrs 10 mo | Naari Pharma Private Limited |
| Hermann Osterwald DIN 06710258 | Nominee Director | 30 Sep 2020 | 6 yrs | Naari Pharma Private Limited |
| Pudhucode Radhakrishnan Kannan DIN 03435209 | Nominee Director | 24 Jul 2025 | 1 yr 2 mo | Naari Pharma Private Limited |
People of Naari
3 people are tracked at Naari (2 in leadership, 1 in team); the tracked headcount is 186.
| Name | Role | Group |
|---|---|---|
Prithi S Kochhar | Co-Founder & Co-CEO | Leadership |
Gulveen Kochhar | Co-CEO | Leadership |
Ankita Chauhan | Executive Human Resources | Team |
Complete people profiles for Naari
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Naari
Figures of Naari Pharma Private Limited, the primary company behind Naari, for FY 2025. Revenue was ₹136 Cr (+14% year on year). Net profit was ₹33.69 Cr (25% margin). EBITDA was ₹40.19 Cr (29% margin). Revenue has grown at a compounded annual rate of +14% over three years and +18% over five years.
- ₹136 CrRevenue · FY 2025 · +14% YoY
- ₹33.69 CrNet profit · 25% margin
- ₹40.19 CrEBITDA · 29% margin
- ₹2.70 CrPaid-up capital
- 186Employees (provident fund records)
- +14%Revenue CAGR, 3 years
- +18%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Naari Pharma Private Limited are on its company page.
Detailed financial statements for Naari
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Naari
5 dated milestones of Naari across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Naari is founded.
- Funding First funding round of $54K.
- Exit Acquired by Tenshi Life Sciences.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Private Equity Round, of $17.5M.
Competitors of Naari
Naari has 8 listed competitors in our database, 8 of them funded. They include Sprout Pharmaceuticals, ObsEva, Hope Medicine, Rejoni and Gameto, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sproutpharmaceuticals.com | 2011 | Raleigh, United States | $185.16M | 31 | Drugs for hypoactive sexual desire disorder in women are developed. | |
| obseva.com | 2012 | Geneva, Switzerland | $94.7M | – | Therapeutics for women's reproductive health and pregnancy are developed. | |
| hopemedinc.com | 2018 | Shanghai, China | $56M | – | Monoclonal antibodies are developed for treating multiple diseases. | |
| rejoni.com | 2020 | Bedford, United States | $41.25M | – | Therapeutics for women's health conditions are developed using innovative hydrogels. | |
| gametogen.com | 2020 | United States | $127M | – | Therapeutics for fertility and menopause treatments are developed. | |
| forendo.com | 2013 | Turku, Finland | $25.58M | – | Small molecule therapeutics for reproductive health are developed. | |
| noratherapeutics.com | 2007 | Palo Alto, United States | $37.81M | – | Therapeutics for IVF failure and recurrent pregnancy loss are developed. | |
| preglem.com | 2006 | Geneva, Switzerland | $57.94M | – | Innovative drugs for women's reproductive medicine are developed and commercialized. |
Detailed competitors of Naari
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Naari
The website of Naari (naari.co) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 16.3% vs previous month
Websites whose visitors overlap most with Naari. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
naaristore.in | naaristore.in | 100% | – | #8,735,856 | – |
naarionlineshopping.com | naarionlineshopping.com | 95% | – | – | – |
Top companies in Women's Health & Fertility
10 companies that operate in the same segment as Naari (Women's Health & Fertility), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Internet first brand offering wearable breast pumps | 2013 | London, England, United Kingdom | USD 157.63 M | – | – | |
Silicone-filled breast and body shaping implants are designed and manufactured. | 2010 | Alajuela, Alajuela, Costa Rica | USD 121 M | USD 211.08 M | 1,020 | |
Immunotherapeutics for cancer and other diseases are developed. | 2008 | Mainz, Rhineland-palatinate, Germany | USD 805.99 M | USD 3.24 B | 6,770 | |
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | Redwood City, California, United States | USD 152.1 M | USD 2.31 B | 4,430 | |
Therapeutics for women's healthcare are developed and offered. | 1997 | Princeton, New Jersey, United States | USD 123.06 M | USD 19.59 M | – | |
Provider of cell-free cancer liquid biopsy test | 2015 | San Francisco, California, United States | USD 388.62 M | – | 861 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Platform for breast ultrasound imaging | 2010 | Plymouth, Massachusetts, United States | USD 136.54 M | – | – | |
Silicone breast implants are developed for reconstruction and aesthetic surgery. | 2007 | Dublin, Ireland | USD 232.81 M | – | – | |
A minimally invasive ablation system for uterine fibroids is developed. | 2005 | Redwood City, California, United States | USD 282.54 M | – | 92 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Naari
Complete news archive for Naari
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Naari
Naari was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Naari is headquartered in Noida, India. It is registered at Noida, Uttar Pradesh, India.
Prithi S Kochhar is the current CEO of Naari. They have also founded this company.
Naari is a funded company, having raised a total of $18.98M across 3 funding rounds to date. The company's 1st funding round was a Grant of $53.69K, raised on Dec 2008.
Naari has 186 employees.
The primary company behind Naari, Naari Pharma Private Limited, reported revenue of ₹136 Cr for FY 2025, up 14% year on year.
Naari manufacturer of women care medicines, focusing on life sciences, women health, drugs, and reproductive diseases. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.
Naari's top competitors include Sprout Pharmaceuticals, Rejoni and Hope Medicine.
Naari has 4 investors. Key investors include Jagsonpal, Ascent Capital, Tenshi Life Sciences, and HUD Exchange.
The valuation of Naari is $86.27M as of Dec 2019.
Naari operates through Naari Pharma Private Limited.
Yes. Naari was acquired by Tenshi Life Sciences in May 2017.